多西他赛联合FOLFOX_6对晚期胃癌疗效观察

The Observation of Advanced Gastric Cancer Treated with Docetaxel Cisplatin and FOLFOX_6

目的:评价多西他赛联合FOLFOX6方案治疗晚期胃癌的疗效及毒副反应。方法:对无法手术的36例Ⅲ～Ⅳ期胃癌患者,应用多西他赛75mg/m2,d1,奥沙利铂(85mg/m2,d1),亚叶酸钙(200mg/m2,静脉注射,d1)、2,5-FU400mg/m2,静脉注射,d1、2,5-FU2400mg/m2,CIV,46h,21d为1个周期。结果:有效率58.3%(21/36),中位TTP时间6.5个月,1年生存率52.8%,生活质量改善69.4%。化疗不良反应主要为骨髓抑制及周围神经毒性,发生率分别为69.4%、55.6%,多为Ⅰ～Ⅱ度。结论:多西他赛联合FOLFOX6治疗晚期胃癌疗效好,不良反应可耐受。

Objective：To evaluate the efficacy and side-effect of Doeetaxel combined with FOLFOX6 in treatment of advanced gastric cancer. Method：36 patients received intravenous Docetaxe175 mg/m2 （ivgtt at d 1）with FOLFOX6（oxaliplatin 85 mg/m2, d 1, CF 200 mg/m2, IV, d 1、 2, 5-FU 400 mg/m2, iv, d 1, 2, 5-FU 2400 mg/m2, CIV, 46 h, the regimen were repeated every 21 days.Result：36 patients were evaluated for response. The overall clinical response rate was 58.3%（21/36）.The time to progression was 5.5 months.Median One year survival rate was 46.5% and 59.5% cases acquired improved life quality.The major toxicity included degree bone marrow inhibition（69.4%）, neurological toxicity（55.6%）.The most are Ⅰ - Ⅱ degree toxicity.Conclusion：The combination of Docetaxel and FOLFOX6 is an effective therapy for the patients with advanced gastric cancer and mild toxicity for patients with advanced gastric cancer.